Top

Reactions Weekly

Published in:

01-01-2023 | Gastric Cancer | Case report

Gimeracil/oteracil/tegafur/nivolumab/oxaliplatin

Pruritus and lack of efficacy: 2 case reports

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Kubota Y, et al. Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience. Cancer Management and Research 14 : 3083-3094, Jan 2022. Available from: URL: http://doi.org/10.2147/CMAR.S351791

Title: Gimeracil/oteracil/tegafur/nivolumab/oxaliplatin
Pruritus and lack of efficacy: 2 case reports
Publication date: 01-01-2023
Publisher: Springer International Publishing
Keywords: Gastric Cancer
Gastric Cancer
Pruritus
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-30793-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Gimeracil/oteracil/tegafur/nivolumab/oxaliplatin

Pruritus and lack of efficacy: 2 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Empagliflozin

Immune-globulin/prednisone

Tozinameran

Sertraline

Doxorubicin

Risk of catatonia greater with first-generation antipsychotics than SGAs